source
- Atea's hepatitis C combo therapy shows non-inferior results to Gilead's EpclusaAtea Pharmaceuticals announced that its oral combination of bemnifosbuvir and ruzasvir met the predefined non-inferiority criteria when compared with Gilead's Epclusa for treating hepatitis C. The…
- Kyverna partners with ElevateBio to supply its autologous CAR-T therapy for autoimmune launchesKyverna Therapeutics has signed a five‑year manufacturing agreement with contract development and manufacturing organization ElevateBio. The deal makes ElevateBio the primary supplier of Kyverna's…